ZETA : Prospective Observational Study

Overview

Primary objective \- Evaluate the efficacy in terms of progression-free survival (PFS) of aflibercept in combination with FOLFIRI in patients treated routinely for metastatic colorectal cancer (mCRC) after failure of treatment with oxaliplatin + EGFR. Secondary objective * Evaluate the efficacy of aflibercept in combination with FOLFIRI on the 2-year overall survival rate and the objective response rate. * Evaluate the tolerance profile of aflibercept in combination with FOLFIRI. * Observational study, national, multicenter, cohort, prospective without intervention on the therapeutic strategy.•

Inclusion criteria * All patients expected to be treated with aflibercept in combination with FOLFIRI for a mCRC, after failure of treatment with oxaliplatin + anti-EGFR on the decision of the doctor (situation included in the framework of the MA of aflibercept) . * Age ≥18 years * Signature of the agreement for the collection of medical and personal data. (Patients who have received FOLFIRINOX in the first line metastatic are allowed) Note: Failure is defined as progression during or within 6 months after discontinuation of oxaliplatin Exclusion criteria : * Concurrent participation in a clinical trial * Patients who have previously received anti-VEGF agents and / or aflibercept in one trial. * Patients who received FOLFIRI in the first metastatic line.

Conditions

Interventions

Eligibility

Locations (2)

Outcomes